Does tipranavir/ritonavir have different effects on body shape and glucose/lipid metabolism, as compared to lopinavir/ritonavir?
Andrew Carr from the host city of Sydney, Australia and the University of New South Wales presented metabolic and body composition results of a Boehringer Ingelheim-sponsored study that compared TPV/r to LPV/r over a short term of 48 weeks in initially ART-naive subjects. All received the thymidine analog-free nuke regimen of tenofovir-3TC with either either a higher ritonavir-boosted TPV regimen (500 mg TPV/200 mg RTV BID) or a lower ritonavir boosted TPV regimen (500 mg TPV/100 mg RTV BID), or Kaletra. Limb fat increased similarly in all 3 groups at week 48, but 48 weeks may not be sufficient time to see a decrease – even with thymidine analog-containing regimens, and there was no week 24 data so it is possible that limb fat had peaked earlier and was on its way down by week 48. However, based in the 96 week results of ACTG 5142 reported earlier this year at CROI (Haubrich, CROI 2007), it is unlikely that the Kaletra group was on its way down in this study so it is probably safe to s
Related Questions
- Does tipranavir/ritonavir have different effects on body shape and glucose/lipid metabolism, as compared to lopinavir/ritonavir?
- Are myo-inositol, glucose and zinc concentrations in amniotic fluid of fetuses with spina bifida different from controls?
- Do glucose and lipid metabolism affect cancer development in Nagasaki atomic bomb survivors?
